First CDK4/6 Inhibitor to Improve Survival in Metastatic Breast Cancer
'Striking, Wonderful' Result
Nick Mulcahy
CHICAGO — It's not often that a systemic oral therapy significantly improves overall survival (OS) in the setting of metastatic cancer.
And, in the case of CDK4/6 inhibitors for breast cancer, it was looking like one might not do so, as multiple previous trials were limited to a significant improvement in progression-free survival.
Sara Hurvitz, MD
So, understandably, there were some smiles among experts discussing the results of the MONALEESA-7 trial in premenopausal women with advanced breast cancer (abstract LBA1008) here during a press conference at the 2019 American Society of Clinical Oncology Annual Meeting.
The CDK4/6 inhibitor ribociclib (Kisqali, Novartis) plus standard-of-care endocrine therapy significantly improved OS for younger women with advanced hormone receptor-positive (HR+) breast cancer compared with endocrine therapy alone, reported lead study author Sara Hurvitz, MD, director, Breast Cancer Clinical Research, UCLA Jonsson Comprehensive Cancer Center, Los Angeles.
It is the first time that a CDK4/6 inhibitor — or any targeted therapy — has been shown in combination with endocrine therapy to significantly improve OS among women with HR+/HER2-negative metastatic disease, she told reporters.
The estimated OS rate at 42 months was 70.2% for women in the combination therapy group vs 46% for women in the endocrine therapy-only group (hazard ratio for death, 0.71; P = .009)
The new findings will be presented in an ASCO session and simultaneously published online June 4 in The New England Journal of Medicine.
The overall survival result, which was part of a planned analysis, crossed the prespecified stopping boundary for superior efficacy.
Advanced breast cancer in this younger population is a "terrible disease" due to its often aggressive nature, said Hurvitz in a meeting press statement.
Harold Burstein, MD, of Dana Farber Cancer Institute, Boston, and an ASCO expert not involved with the study told reporters that "the golden age of clinical research in oncology continues."
A theme seen in the new study and others, he added, is "that with mature and robust data, we are now seeing substantial improvements in survival with innovative drugs that are coming to market."
At a pre-meeting press event, Monica Bertagnolli, MD, chief of surgical oncology, Dana Farber Cancer Institute, and ASCO president called the results "striking and wonderful" and observed that the 42-month data amount to 3.5 years, which is "a lot" of time in advanced breast cancer.
Previously, ribociclib was approved in 2017 by the US Food and Drug Administration for use in advanced HR+ breast cancer in post-menopausal women and, in 2018, for similar use in premenopausal women on the basis of earlier progression-free survival results from this same MONALEESA-7 trial.
Charles Shapiro, MD, director of translational breast cancer research and cancer survivorship, Tisch Cancer Institute at Mount Sinai, New York City, commented on the new results: "This is going to represent a new standard of care for metastatic premenopausal women with hormone receptor-positive breast cancers."
Shapiro, who was not involved in the study, told Medscape Medical News that it is "an excellent question whether there any differences between the three CDK 4/6 inhibitors. Thus far there are no direct comparisons among them." This was a reference to palbociclib (Ibrance, Pfizer) and abemaciclib (Verzenio, Lilly) , the other members of this class of drugs.
Combination therapy in this premenopausal setting "will likely work" with other CDK 4/6 inhibitors, he added.
Agreed, said Dawn Hershman, MD, leader of the breast cancer program at Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York City, who was asked for comment.
All of the drugs in this class would probably have a similar effect "if studied using the same criteria and length of time," said Hershman, who was not involved in the study. "It's hard to believe they wouldn't," she told Medscape Medical News.
This was, in part, a reference to the fact that palbociclib was shown to improve overall survival in the PALOMA-3 trial but not significantly so. But PALOMA-3 included both post- and pre-menopausal women, who were more heavily pretreated than the women in the current trial. Indeed, in MONALEESA-7, all of the women were receiving initial endocrine therapy and only 15% had received previous chemotherapy.
However, Hurvitz defended ribociclib's newly established status in this setting during the press conference.
She said that medical oncologists have generally been "comfortable using these drugs [CDK 4/6 inhibitors] interchangeably" with these patients but, with the overall survival improvement now seen with ribociclib, other agents will have to demonstrate the same.
Study Details
MONALEESA-7 is the first trial to focus exclusively premenopausal women (< age 59 years) with advanced breast cancer who had not received prior endocrine therapy.
In the trial, investigators randomly assigned 672 women to the oral therapy ribociclib or to a placebo pill. All women also received the injectable endocrine therapy goserelin, and one of three other endocrine therapies: the aromatase inhibitors letrozole or anastrozole or the selective estrogen receptor modulator tamoxifen.
After a median follow-up of 34.6 months, 173 (26%) continued to receive treatment, but with 116 (35%) of the women still receiving ribociclib vs only 57 (17%) still receiving the placebo.
In addition, the investigators broke down the survival data by the two types of oral endocrine therapies used in the trial. They report survival rates of 71% and 70% for women who took ribociclib in combination with tamoxifen or an aromatase inhibitor, respectively, compared with a survival rate of 55% and 43%, respectively, for women who received placebo in combination with tamoxifen or aromatase inhibitors only.
No new safety signals were observed during the median of 2 years of treatment exposure in the combination therapy group, said the study authors.
The study also serves another purpose for clinicians and patients, said Dana Farber's Burstein.
"One of the myths that this study helps suppress is that younger [women] with ER+ breast cancer have a fundamentally different outcome than older women — actually their outcomes look very similar," he said, referring to earlier ribociclib research among postmenopausal women, including PALOMA-3 trial.
The study was funded by Novartis, makers of ribociclib. Study authors including Hurvitz have financial ties to the company and include Novartis employees. Shapiro, Hershman, and Burstein have disclosed no relevant financial relationships.
2019 American Society of Clinical Oncology (ASCO) Annual Meeting: Abstract LBA1008. Presented June 4, 2019.
N Engl J Med. Published online June 4, 2019. Abstract
Follow Medscape's Nick Mulcahy on Twitter.
For more Medscape Oncology news, join us on Facebook and Twitter.
lunes, 17 de junio de 2019
sábado, 15 de junio de 2019
Personalized Eating: The 'New' Diet?
Heidi Nelson, MD
Perspective > Medscape
Personalized Eating: The 'New' Diet?
We have long assumed that the same "healthy" diet was healthy for everyone. But what if the food you are eating is all wrong for your body?
Welcome to personalized nutrition, an emerging field using a mix of science and technology that determines what foods are good or bad for you by designing an individualized diet. In just the past few years, the research has overturned conventional wisdom surrounding nutrition and may soon entirely collapse the monolithic dietary guidance upon which we've relied to date.
Although the definition of "personalized nutrition" is still evolving, it has been concisely described as "an approach that uses information on individual characteristics to develop targeted nutritional advice, products, or services."[1] Those "individual characteristics" can include physiologic features (eg, age, gender), fluctuating environmental factors (eg, sleep patterns, physical activity), more cutting-edge insights obtained by assessing a person's genetic or microbiome profile, or some combination thereof.
On its own, this information may not seem to have much disruptive power. Yet, using "big data" collected from thousands of people around the world to create algorithm-based prediction models has revealed surprising disparities in how individuals respond to different foods.
Eran Elinav, MD, PhD
We are only in the early stages of understanding how individuals respond to specific foods, with the best available data focusing on glycemic outcomes, yet there is considerable optimism that personalized nutrition will become an invaluable tool for helping patients decide what to include and exclude from their plates to maintain overall health and manage or prevent disease.
"We envision that in 5-10 years, one-size-fits-all diets would become obsolete and be replaced by diets that will be based on a combination of individual host and microbiome features, the medical condition to be treated, and personal preferences," said Eran Elinav, MD, PhD, a professor of immunology at the Weizmann Institute of Science in Israel, and a pioneer in the field.
State of Personalized Nutrition Science
So far, the most compelling data on the promise of personalized nutrition have come from studies incorporating the gut microbiome profile. These raise the tantalizing possibility that the information gleaned from a simple stool sample can help predict responses to specific foods.
Elinav and colleagues tested this theory in a watershed three-part study focusing on postprandial glycemic responses (PPGRs).[2] First, they enrolled 800 participants from Israel and tested glucose after every meal they consumed, confirming that PPGRs varied considerably among them, even when they ate identical foods. Next, they incorporated all the information they obtained from this cohort into an algorithm, along with other factors, such as age, weight, and microbiome profiles, and validated the algorithm's ability to accurately predict PPGRs in a separate, smaller cohort. Finally, they confirmed the algorithm's real-world value in a blinded, randomized study, in which microbiomes and clinical information were used to create customized diets for each participant based on that person's predicted PPGR to foods. The algorithm-designed diets resulted in significantly lower PPGRs. Thus, the study made a compelling case for proof of concept, validity, and applicability, all in one publication.
"Although the concept of interpersonal differences in response to food has been previously described, we believe that formulating individual host and microbiome features into dietary recommendations in a large cohort in an evidence-based manner was unprecedented and revolutionized the outlook on nutrition," Elinav said.
This is particularly important, according to Heidi Nelson, MD, who leads the Center for Individualized Medicine Microbiome Program at the Mayo Clinic in Rochester, Minnesota, and is one of the authors of this study, because it replaces the relatively uninformative averages on which nutritional advice is based with precise variable-derived predictions.
"We want to know whether someone is a low or high responder to various foods, because you can substitute high-response foods with another food, or avoid those foods entirely. We've also shown that in some cases, combining foods lowers the glycemic response. Sometimes a few almonds added into a certain food mitigated the glycemic response," she said.
Commercialization Before Validation Raises Concerns
Although these forays into personalized nutrition have garnered significant attention, concern remains that expectations for its actual application may be unrealistic at present. But commercial entities aren't waiting for more data; they have already begun marketing these tools to the general public.
DayTwo, Inc., is using the technology to provide personalized nutrition recommendations that predict a person's glycemic response to various foods. It's as simple as buying a kit and mailing in a stool sample. After testing the stool, DayTwo claims to provide access to dietary advice that can help modify outcomes ranging from weight loss and gastrointestinal symptoms (eg, bloating, constipation) to mental and immunologic health. Other companies offer broadly comparable services, but their prediction tools haven't been vetted in the peer-reviewed literature to the same level.[2]
Several personalized nutrition companies—for example, Habit, GenoPalate, Nutrogenomix, and Profile—focus on DNA testing. Though they differ in their offerings, the basic pitch is the same. Consumers purchase a kit, either through the mail or at a brick-and-mortar location, which they use to provide blood samples and/or cheek swabs. The kits are sent to the companies, which then analyze the person's genotype and phenotype and compare them against established genetic markers. Consumers are informed what foods are right for them based on their predicted ability to metabolize them, which nutrients they should be seeking and avoiding, and what is likely to result in the most weight loss. Advice comes in printed reports or on digital apps, right down to personalized recipes.
These kits range in price from $150 to $350, although add-on features (memberships, extended coaching sessions with dietitians, and foods and supplements offered by the companies) are also available. These companies are doing more than selling a one-time curiosity product; they are establishing relationships with consumers to provide long-term health advice. The model is some combination of genetic information providers, such as 23andMe or Ancestery.com, and popular weight-loss institutions, such as Jenny Craig or Weight Watchers. It's easy to envision why this would be intriguing to both consumers and investors. However, their websites are often vague about what they can provide or the science underlying their services.
"My discomfort is that these proprietary methods have gone into full commercialization before any real validation has occurred," said Alexander Khoruts, MD, a scientific advisory board member for the American Gastroenterological Association Center for Gut Microbiome Research & Education and medical director of the Microbiota Therapeutics Program at the University of Minnesota in Minneapolis.
Other researchers are similarly dismayed by the claims some companies are making in the absence of large-scale validation studies.
"Personalized nutrition services should be scrutinized," said Elinav. "Constituents other than glucose, such as fat, protein, vitamins, and minerals, should be taken into account in dietary planning. Food allergies and other individual considerations shouldn't be overlooked. Blindly following automated reports is never advisable."
They are also largely in agreement about the key limitations of personalized nutrition research to date. Khoruts identified one of the lingering issues to be the lack of standardization among testing kits. Elinav agreed with this characterization, noting that whereas standardization has been achieved in his own model, it is a bigger concern with more inadequately studied direct-to-consumer kits.
How Personalized Nutrition Can Realize Its Potential
Nonetheless, Khoruts acknowledges that because of these direct-to-consumer services, physicians are likely to encounter more patients asking about them.
"Gastroenterologists are seeing patients who bring in these reports to the office, because the companies are marketing directly to consumers. They have pretty websites that promise a lot," he said.
The trouble is that the reports are difficult to explain to patients, even for an expert such as Khoruts. For those incorporating microbiome analyses, patients are often told whether their profiles are within ranges considered normal, when in fact sufficient analyses have not yet been provided to establish these ranges convincingly. This means these reports offer little actionable advice for physicians to work with, although Khoruts does see their value in simply generating productive interactions with patients.
"If patients are engaged and are doing some of this research on their own to seek answers, it is also an opportunity for a physician to engage in conversation with the patient."
Elinav added that reports generated by a personalized nutrition company should never replace common sense. "They should be integrated into the armamentarium of physicians and medical personnel as an auxiliary evidence-based means to enhance precision in dietary planning," he said.
Regardless of these current limitations, the potential to use this research to inform diagnosis and treatment is considerable, given the microbiome's hypothesized role in so many elements of human health, such as cancer progression, infection susceptibility, inflammatory bowel disease, neurologic disorders, and metabolic conditions, said Elinav.
Nelson added that perhaps the most important thing to remember is that this is a young field of science that will take time to sort out.
To fulfill its promise, more well-designed studies of the type conducted by Elinav, Nelson, and others are needed, and perhaps a little less of the hype coming from the commercial side of this field.
Follow Medscape on Facebook, Twitter, Instagram, and YouTube
Perspective > Medscape
Personalized Eating: The 'New' Diet?
We have long assumed that the same "healthy" diet was healthy for everyone. But what if the food you are eating is all wrong for your body?
Welcome to personalized nutrition, an emerging field using a mix of science and technology that determines what foods are good or bad for you by designing an individualized diet. In just the past few years, the research has overturned conventional wisdom surrounding nutrition and may soon entirely collapse the monolithic dietary guidance upon which we've relied to date.
Although the definition of "personalized nutrition" is still evolving, it has been concisely described as "an approach that uses information on individual characteristics to develop targeted nutritional advice, products, or services."[1] Those "individual characteristics" can include physiologic features (eg, age, gender), fluctuating environmental factors (eg, sleep patterns, physical activity), more cutting-edge insights obtained by assessing a person's genetic or microbiome profile, or some combination thereof.
On its own, this information may not seem to have much disruptive power. Yet, using "big data" collected from thousands of people around the world to create algorithm-based prediction models has revealed surprising disparities in how individuals respond to different foods.
Eran Elinav, MD, PhD
We are only in the early stages of understanding how individuals respond to specific foods, with the best available data focusing on glycemic outcomes, yet there is considerable optimism that personalized nutrition will become an invaluable tool for helping patients decide what to include and exclude from their plates to maintain overall health and manage or prevent disease.
"We envision that in 5-10 years, one-size-fits-all diets would become obsolete and be replaced by diets that will be based on a combination of individual host and microbiome features, the medical condition to be treated, and personal preferences," said Eran Elinav, MD, PhD, a professor of immunology at the Weizmann Institute of Science in Israel, and a pioneer in the field.
State of Personalized Nutrition Science
So far, the most compelling data on the promise of personalized nutrition have come from studies incorporating the gut microbiome profile. These raise the tantalizing possibility that the information gleaned from a simple stool sample can help predict responses to specific foods.
Elinav and colleagues tested this theory in a watershed three-part study focusing on postprandial glycemic responses (PPGRs).[2] First, they enrolled 800 participants from Israel and tested glucose after every meal they consumed, confirming that PPGRs varied considerably among them, even when they ate identical foods. Next, they incorporated all the information they obtained from this cohort into an algorithm, along with other factors, such as age, weight, and microbiome profiles, and validated the algorithm's ability to accurately predict PPGRs in a separate, smaller cohort. Finally, they confirmed the algorithm's real-world value in a blinded, randomized study, in which microbiomes and clinical information were used to create customized diets for each participant based on that person's predicted PPGR to foods. The algorithm-designed diets resulted in significantly lower PPGRs. Thus, the study made a compelling case for proof of concept, validity, and applicability, all in one publication.
"Although the concept of interpersonal differences in response to food has been previously described, we believe that formulating individual host and microbiome features into dietary recommendations in a large cohort in an evidence-based manner was unprecedented and revolutionized the outlook on nutrition," Elinav said.
This is particularly important, according to Heidi Nelson, MD, who leads the Center for Individualized Medicine Microbiome Program at the Mayo Clinic in Rochester, Minnesota, and is one of the authors of this study, because it replaces the relatively uninformative averages on which nutritional advice is based with precise variable-derived predictions.
"We want to know whether someone is a low or high responder to various foods, because you can substitute high-response foods with another food, or avoid those foods entirely. We've also shown that in some cases, combining foods lowers the glycemic response. Sometimes a few almonds added into a certain food mitigated the glycemic response," she said.
Commercialization Before Validation Raises Concerns
Although these forays into personalized nutrition have garnered significant attention, concern remains that expectations for its actual application may be unrealistic at present. But commercial entities aren't waiting for more data; they have already begun marketing these tools to the general public.
DayTwo, Inc., is using the technology to provide personalized nutrition recommendations that predict a person's glycemic response to various foods. It's as simple as buying a kit and mailing in a stool sample. After testing the stool, DayTwo claims to provide access to dietary advice that can help modify outcomes ranging from weight loss and gastrointestinal symptoms (eg, bloating, constipation) to mental and immunologic health. Other companies offer broadly comparable services, but their prediction tools haven't been vetted in the peer-reviewed literature to the same level.[2]
Several personalized nutrition companies—for example, Habit, GenoPalate, Nutrogenomix, and Profile—focus on DNA testing. Though they differ in their offerings, the basic pitch is the same. Consumers purchase a kit, either through the mail or at a brick-and-mortar location, which they use to provide blood samples and/or cheek swabs. The kits are sent to the companies, which then analyze the person's genotype and phenotype and compare them against established genetic markers. Consumers are informed what foods are right for them based on their predicted ability to metabolize them, which nutrients they should be seeking and avoiding, and what is likely to result in the most weight loss. Advice comes in printed reports or on digital apps, right down to personalized recipes.
These kits range in price from $150 to $350, although add-on features (memberships, extended coaching sessions with dietitians, and foods and supplements offered by the companies) are also available. These companies are doing more than selling a one-time curiosity product; they are establishing relationships with consumers to provide long-term health advice. The model is some combination of genetic information providers, such as 23andMe or Ancestery.com, and popular weight-loss institutions, such as Jenny Craig or Weight Watchers. It's easy to envision why this would be intriguing to both consumers and investors. However, their websites are often vague about what they can provide or the science underlying their services.
"My discomfort is that these proprietary methods have gone into full commercialization before any real validation has occurred," said Alexander Khoruts, MD, a scientific advisory board member for the American Gastroenterological Association Center for Gut Microbiome Research & Education and medical director of the Microbiota Therapeutics Program at the University of Minnesota in Minneapolis.
Other researchers are similarly dismayed by the claims some companies are making in the absence of large-scale validation studies.
"Personalized nutrition services should be scrutinized," said Elinav. "Constituents other than glucose, such as fat, protein, vitamins, and minerals, should be taken into account in dietary planning. Food allergies and other individual considerations shouldn't be overlooked. Blindly following automated reports is never advisable."
They are also largely in agreement about the key limitations of personalized nutrition research to date. Khoruts identified one of the lingering issues to be the lack of standardization among testing kits. Elinav agreed with this characterization, noting that whereas standardization has been achieved in his own model, it is a bigger concern with more inadequately studied direct-to-consumer kits.
How Personalized Nutrition Can Realize Its Potential
Nonetheless, Khoruts acknowledges that because of these direct-to-consumer services, physicians are likely to encounter more patients asking about them.
"Gastroenterologists are seeing patients who bring in these reports to the office, because the companies are marketing directly to consumers. They have pretty websites that promise a lot," he said.
The trouble is that the reports are difficult to explain to patients, even for an expert such as Khoruts. For those incorporating microbiome analyses, patients are often told whether their profiles are within ranges considered normal, when in fact sufficient analyses have not yet been provided to establish these ranges convincingly. This means these reports offer little actionable advice for physicians to work with, although Khoruts does see their value in simply generating productive interactions with patients.
"If patients are engaged and are doing some of this research on their own to seek answers, it is also an opportunity for a physician to engage in conversation with the patient."
Elinav added that reports generated by a personalized nutrition company should never replace common sense. "They should be integrated into the armamentarium of physicians and medical personnel as an auxiliary evidence-based means to enhance precision in dietary planning," he said.
Regardless of these current limitations, the potential to use this research to inform diagnosis and treatment is considerable, given the microbiome's hypothesized role in so many elements of human health, such as cancer progression, infection susceptibility, inflammatory bowel disease, neurologic disorders, and metabolic conditions, said Elinav.
Nelson added that perhaps the most important thing to remember is that this is a young field of science that will take time to sort out.
To fulfill its promise, more well-designed studies of the type conducted by Elinav, Nelson, and others are needed, and perhaps a little less of the hype coming from the commercial side of this field.
Follow Medscape on Facebook, Twitter, Instagram, and YouTube
sábado, 9 de marzo de 2019
Dr. Rubens Riotorto Bellomo Medical Oncologist CV
Dr. Rubens Riotorto Bellomo
Medical Oncologist
Medical Oncologist
Compassionate and dedicated professional with extensive experience diagnosing and treating cancer across hospitals and clinical settings. Well-versed in improving patient’s lives, delivering palliative care, interfacing with radiotherapy team, and recommending effective medical oncology treatments regarding bowel, breast, and lung cancer. Proficient in meeting co-ordination, budgeting, consultancy services, case, personnel, and project management. Possess multi-lingual proficiencies in Spanish, English, French, Italian, and Portuguese.
Professional Experience
CHU UCL Louvain, Dinant
Medical Oncologist, 2018
Headed departmental functions at the Day Medical Hospital to accomplish bottom-line results. Assisted four multi-disciplinary meetings regarding breast, gynaecology, colon, and dermatology with St. Elizabeth and Mt. Godinne centres.
Provided robust consultancy services to patients.
Managed patients’ medical oncology treatments.
Genesis Care Group, Spain
Medical Oncologist, 2015–2018
Recommended treatments to cancer patients at Algeciras Clinic in Radon Clinic Algeciras. Discussed patients’ condition with radiotherapy team and proposed RT treatment by interfacing with radiotherapist specialist at Algeciras Clinic.
Conducted follow up visits to oncologic outpatients with all solid tumours and newly cancer patients at Quore Clinic.
Attended weekly MDT meeting and mentored admitted oncologic patients across Clinica La Salud Cadiz.
Clinica Diagonal, Barcelona, Spain
Medical Oncologist, 2012–2015
Delivered solid tumours and chemotherapy services to newly diagnosed cancer patients. Controlled toxicity management. Participated in multi-disciplinary meeting and discussed oncologic patients’ history with general surgeon, radiologist, pathologist, internal medicine, psycologist, and nurse.
Managed solid tumours service with follow up visits.
Hospital Santos Reyes, Aranda de Duero, Burgos
In charge - Tumor Registry, 2010–2011
Gathered and upheld appropriate diagnostic, therapeutic, and survival data on patients with neoplastic diseases while attending regular meetings of the central Tumor Registry in Burgos.
Technical Commission, Spanish Association against Cancer, Melilla, Spain
President, 2008–2009
Provided expert opinion to board of directors on technical aspects of actions of Association.
Hospital Comarcal de Melilla, Spain
Medical Oncologist, 2006–2009
Saw patients with all solid tumors at a Day Hospital to give all medical oncology treatments available at Hospital on a daily basis. Administered patients with follow up visits and newly diagnosed cancer patients. Managed all the patients with an oncologic diagnosis admitted at Hospital and supervised inpatient chemotherapy, toxicity, and palliative care. Oversaw admissions and review of internal medicine patients admitted to Hospital with all internal medicine pathology. Managed all kind of emergency patients including children.
Credited for providing oncology service to about 85K inhabitants within a city.
Additional Experience:
Consultant Assistant, USP Dexeus University Institute, Barcelona | Hospital of Barcelona, Assistencia Sanitaria
Committee Member, Tumor Committee, Hospital Santos Reyes, Aranda de Duero, Burgos
Member of the Breast Pathology Unit, Hospital Santos Reyes, Aranda de duero
Medical Oncologist, Hospital Santos Reyes, Aranda de Duero, Burgos, Spain
Secretary, Tumor Registry Commission, Hospital Comarcal de Melilla, Spain
Medical Oncologist, Asociación Española Primera de Socorros Mutuos, Montevideo, Uruguay
Director, National Institute of Oncology, Ministry of Public Health, Montevideo Uruguay
Committe Member, Comisión Honoraria de Lucha contra el Cancer, Montevideo, Uruguay
Head of Department, Department of Medical Oncology, Instituto Nacional de Oncología, Montevideo Uruguay
Commitee Member, Central Tumor Comittee, (Dirección General de la Administración de Servicios de Salud del Estado), Ministry of Public Health, Montevideo, Uruguay
Committee Member, Advisor Committe for purchases of Antitumor medications, Instituto Nacional de Oncología, Montevideo, Uruguay
Medical Advisor, Anti- tumor National medication Bank, Instituto Nacional de Oncología, Montevideo Uruguay
Advisor, Technical education for Professionals, Comisión Honoraria de Lucha contra el Cáncer, Montevideo, Uruguay
Committee Member, Climateric Commission Ministry of Public Health, Montevideo, Uruguay
Head of Department, Chemotherapy Service, Instituto Nacional de Oncologia
Designed Medical Doctor, Instituto Nacional de Oncología
Education & Credentials
Medical Oncology
Graduate School of Facultad de Medicina de la República Oriental del Uruguay – Montevideo Uruguay
homologation diplomes In Spain, UK and Belgium
Degree of Medical Doctor
Universidad de la República Oriental del Uruguay –Montevideo Uruguay
homologation diplomes In Spain, UK and Belgium
Professional Development Program for Goverment Employees of Oficina Nacional del Registro Civil
Honorary Collaborator, Immunology Department, Facultad de Química, Montevideo Uruguay under the Supervision of Fernando Goñi in the area of Immunoglobulins & Cancer
Aguarded with a scholarship by Insituto Nacional de Oncología and Comisión Honoraria de Lucha contra el Cáncer at the INSTITUT CURIE of Paris reporting to Prof. Dr. Pierre Pouillart
Courses & Conferences Attended
European Congress 2018 Munich, Germany; European Cancer Congress 2017, Madrid, Spain; ESMO Congress, Copenhagen, Denmark; VI Symposium SOGUG (Spanish Genitourinary Group); Vienna, European Cancer Congress 2015 (ECC 2015); V Symposisum SOGUG; Madrid. ESMO Congress; Madrid, IV Symposium SOGUG; 15th World Congress On Gastrointestinal Cancer, Barcelona; Praga, Prostate Cancer up to date. AGUCC Congress; Updates on Cancer. Dr. Díaz Rubio, Madrid; Intrernational Meeting in Cambridge: Advances on Brest Cancer, UK; 5th EAN- EGFR Advisors Network Meeting, Netherlands
Professional Associations
Member: Spanish Oncology Genitourinary Group, European Society of Medical Oncology, Sociedad Española de Oncología Médica
Publication
1. 1995 ASCO Annual Meeting Abstract N: 730. Authors: E Lasalvia, S Cuchi, T Carlevaro, J Vazquez, R Riotorto, L Fierro, Antimetastatic effect of a blood fraction from cancer patients (Meeting Abstract). 2006.
2. Phase II, open-label, randomized study (SIGN) of single agent Gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) nbon-small-cell lung cancer. Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K; on behalf of the SIGN study proup, Principal resercher for Uruguay. Fase II Gefitinib.
3. Anales de Otorrinolaringología del Uruguay, Tomo LXXXI-2004-29 Importancia del Factor de Crecimiento Epidérmico en Oncología. Caso Clínico. Authors: Falconi E; Riotorto R, García E.
4. Communication in the 57 Congress of the National Society of Spanish Hospital Pharmacy. “Usefulness of Cystatin C for Therapeutic Drug Monitoring of Amikacin in an Oncologic Patient”. Authors: Rebollo Díaz N; Moreno Gómez AM; Revilla Cuesta N; Riotorto Bellomo RE; Cepeda Piorno J.Rubens Riotorto Bellomo
Anhée
ruriotorto@gmail.com +32460977053
Personal Details:
March 3rd, 1955 Montevideo Spain
4. Male Spanish Citizenship
Medical Oncologist
Medical Oncologist
Compassionate and dedicated professional with extensive experience diagnosing and treating cancer across hospitals and clinical settings. Well-versed in improving patient’s lives, delivering palliative care, interfacing with radiotherapy team, and recommending effective medical oncology treatments regarding bowel, breast, and lung cancer. Proficient in meeting co-ordination, budgeting, consultancy services, case, personnel, and project management. Possess multi-lingual proficiencies in Spanish, English, French, Italian, and Portuguese.
Professional Experience
CHU UCL Louvain, Dinant
Medical Oncologist, 2018
Headed departmental functions at the Day Medical Hospital to accomplish bottom-line results. Assisted four multi-disciplinary meetings regarding breast, gynaecology, colon, and dermatology with St. Elizabeth and Mt. Godinne centres.
Provided robust consultancy services to patients.
Managed patients’ medical oncology treatments.
Genesis Care Group, Spain
Medical Oncologist, 2015–2018
Recommended treatments to cancer patients at Algeciras Clinic in Radon Clinic Algeciras. Discussed patients’ condition with radiotherapy team and proposed RT treatment by interfacing with radiotherapist specialist at Algeciras Clinic.
Conducted follow up visits to oncologic outpatients with all solid tumours and newly cancer patients at Quore Clinic.
Attended weekly MDT meeting and mentored admitted oncologic patients across Clinica La Salud Cadiz.
Clinica Diagonal, Barcelona, Spain
Medical Oncologist, 2012–2015
Delivered solid tumours and chemotherapy services to newly diagnosed cancer patients. Controlled toxicity management. Participated in multi-disciplinary meeting and discussed oncologic patients’ history with general surgeon, radiologist, pathologist, internal medicine, psycologist, and nurse.
Managed solid tumours service with follow up visits.
Hospital Santos Reyes, Aranda de Duero, Burgos
In charge - Tumor Registry, 2010–2011
Gathered and upheld appropriate diagnostic, therapeutic, and survival data on patients with neoplastic diseases while attending regular meetings of the central Tumor Registry in Burgos.
Technical Commission, Spanish Association against Cancer, Melilla, Spain
President, 2008–2009
Provided expert opinion to board of directors on technical aspects of actions of Association.
Hospital Comarcal de Melilla, Spain
Medical Oncologist, 2006–2009
Saw patients with all solid tumors at a Day Hospital to give all medical oncology treatments available at Hospital on a daily basis. Administered patients with follow up visits and newly diagnosed cancer patients. Managed all the patients with an oncologic diagnosis admitted at Hospital and supervised inpatient chemotherapy, toxicity, and palliative care. Oversaw admissions and review of internal medicine patients admitted to Hospital with all internal medicine pathology. Managed all kind of emergency patients including children.
Credited for providing oncology service to about 85K inhabitants within a city.
Additional Experience:
Consultant Assistant, USP Dexeus University Institute, Barcelona | Hospital of Barcelona, Assistencia Sanitaria
Committee Member, Tumor Committee, Hospital Santos Reyes, Aranda de Duero, Burgos
Member of the Breast Pathology Unit, Hospital Santos Reyes, Aranda de duero
Medical Oncologist, Hospital Santos Reyes, Aranda de Duero, Burgos, Spain
Secretary, Tumor Registry Commission, Hospital Comarcal de Melilla, Spain
Medical Oncologist, Asociación Española Primera de Socorros Mutuos, Montevideo, Uruguay
Director, National Institute of Oncology, Ministry of Public Health, Montevideo Uruguay
Committe Member, Comisión Honoraria de Lucha contra el Cancer, Montevideo, Uruguay
Head of Department, Department of Medical Oncology, Instituto Nacional de Oncología, Montevideo Uruguay
Commitee Member, Central Tumor Comittee, (Dirección General de la Administración de Servicios de Salud del Estado), Ministry of Public Health, Montevideo, Uruguay
Committee Member, Advisor Committe for purchases of Antitumor medications, Instituto Nacional de Oncología, Montevideo, Uruguay
Medical Advisor, Anti- tumor National medication Bank, Instituto Nacional de Oncología, Montevideo Uruguay
Advisor, Technical education for Professionals, Comisión Honoraria de Lucha contra el Cáncer, Montevideo, Uruguay
Committee Member, Climateric Commission Ministry of Public Health, Montevideo, Uruguay
Head of Department, Chemotherapy Service, Instituto Nacional de Oncologia
Designed Medical Doctor, Instituto Nacional de Oncología
Education & Credentials
Medical Oncology
Graduate School of Facultad de Medicina de la República Oriental del Uruguay – Montevideo Uruguay
homologation diplomes In Spain, UK and Belgium
Degree of Medical Doctor
Universidad de la República Oriental del Uruguay –Montevideo Uruguay
homologation diplomes In Spain, UK and Belgium
Professional Development Program for Goverment Employees of Oficina Nacional del Registro Civil
Honorary Collaborator, Immunology Department, Facultad de Química, Montevideo Uruguay under the Supervision of Fernando Goñi in the area of Immunoglobulins & Cancer
Aguarded with a scholarship by Insituto Nacional de Oncología and Comisión Honoraria de Lucha contra el Cáncer at the INSTITUT CURIE of Paris reporting to Prof. Dr. Pierre Pouillart
Courses & Conferences Attended
European Congress 2018 Munich, Germany; European Cancer Congress 2017, Madrid, Spain; ESMO Congress, Copenhagen, Denmark; VI Symposium SOGUG (Spanish Genitourinary Group); Vienna, European Cancer Congress 2015 (ECC 2015); V Symposisum SOGUG; Madrid. ESMO Congress; Madrid, IV Symposium SOGUG; 15th World Congress On Gastrointestinal Cancer, Barcelona; Praga, Prostate Cancer up to date. AGUCC Congress; Updates on Cancer. Dr. Díaz Rubio, Madrid; Intrernational Meeting in Cambridge: Advances on Brest Cancer, UK; 5th EAN- EGFR Advisors Network Meeting, Netherlands
Professional Associations
Member: Spanish Oncology Genitourinary Group, European Society of Medical Oncology, Sociedad Española de Oncología Médica
Publication
1. 1995 ASCO Annual Meeting Abstract N: 730. Authors: E Lasalvia, S Cuchi, T Carlevaro, J Vazquez, R Riotorto, L Fierro, Antimetastatic effect of a blood fraction from cancer patients (Meeting Abstract). 2006.
2. Phase II, open-label, randomized study (SIGN) of single agent Gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) nbon-small-cell lung cancer. Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K; on behalf of the SIGN study proup, Principal resercher for Uruguay. Fase II Gefitinib.
3. Anales de Otorrinolaringología del Uruguay, Tomo LXXXI-2004-29 Importancia del Factor de Crecimiento Epidérmico en Oncología. Caso Clínico. Authors: Falconi E; Riotorto R, García E.
4. Communication in the 57 Congress of the National Society of Spanish Hospital Pharmacy. “Usefulness of Cystatin C for Therapeutic Drug Monitoring of Amikacin in an Oncologic Patient”. Authors: Rebollo Díaz N; Moreno Gómez AM; Revilla Cuesta N; Riotorto Bellomo RE; Cepeda Piorno J.Rubens Riotorto Bellomo
Anhée
ruriotorto@gmail.com +32460977053
Personal Details:
March 3rd, 1955 Montevideo Spain
4. Male Spanish Citizenship
Suscribirse a:
Entradas (Atom)